AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24400341 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training & Alagebrium (200 mg/day)
Number of subjects: 48
Study 24400341 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training & placebo
Number of subjects: 48
Study 24400341 — intervention group
Group type: COMPARATOR
Intervention: No exercise training & Alagebrium (200 mg/day)
Number of subjects: 48
Study 24400341 — intervention group
Group type: COMPARATOR
Intervention: No exercise training & placebo
Number of subjects: 48
Study 21501129 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 180
Study 21501129 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 180
Study 19304990 — intervention group
Group type: EXPERIMENTAL
Intervention: Body surface area (BSA) at age 20, midlife BMI, and weight gain from age 20 to midlife
Number of subjects: 6903
Study 19304990 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain from age 20 to midlife
Number of subjects: 6903
Study 16984235 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I/IGFBP‐3 complex (SomatoKine) 0.4 mg/kg/day
Number of subjects: 6
Study 16984235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 15533733 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg once daily)
Number of subjects: 41
Study 15533733 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine coat-core (20 mg once daily)
Number of subjects: 41
Study 11684410 — intervention group
Group type: EXPERIMENTAL
Intervention: Same Size (100 kcal)
Number of subjects: 12
Study 11684410 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Liquid Meal (100 kcal)
Number of subjects: 12
Study 11684410 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Meal (847 kcal)
Number of subjects: 12
Study 11684410 — intervention group
Group type: COMPARATOR
Intervention: Fasted Phase
Number of subjects: 12
Study 9290963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rifampicin 600 mg plus ofloxacin 400 mg plus minocycline 100 mg (ROM) administered as single dose
Number of subjects: 1483
Study 9290963 — intervention group
Group type: COMPARATOR
Intervention: Standard six-month WHO/MDT/PB regimen
Number of subjects: 1483
Study 8300461 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate inhaler (50 ug) 2 puffs qds
Number of subjects: 44
Study 8300461 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol inhaler (100 mcg) 2 puffs tds
Number of subjects: 44
Study 3572629 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula B (3.6 g/kg/d protein, 115 kcal/kg/d energy)
Number of subjects: 19
Study 3572629 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula C (3.5 g/kg/d protein, 149 kcal/kg/d energy)
Number of subjects: 19
Study 3572629 — intervention group
Group type: COMPARATOR
Intervention: Formula A (2.24 g/kg/d protein, 113 kcal/kg/d energy)
Number of subjects: 19
Study 3572629 — intervention group
Group type: COMPARATOR
Intervention: Formula B vs Formula A
Number of subjects: 19
Study 3572629 — intervention group
Group type: COMPARATOR
Intervention: Formula C vs Formula B
Number of subjects: 19
Study 3572629 — intervention group
Group type: COMPARATOR
Intervention: Formula A and C
Number of subjects: 19
Study 29096069 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit exercise training (3 times a week, 45-90 min, intensity 50%-90% peak oxygen uptake for 4 weeks)
Number of subjects: 70
Study 29096069 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit exercise training (3 times a week, 45-90 min, intensity 50%-90% peak oxygen uptake for 8 weeks)
Number of subjects: 70
Study 29096069 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit exercise training (4 weeks and 8 weeks)
Number of subjects: 70
Study 26323598 — intervention group
Group type: EXPERIMENTAL
Intervention: rs9346455
Number of subjects: 189
Study 26323598 — intervention group
Group type: EXPERIMENTAL
Intervention: rs7336345
Number of subjects: 189
Study 26323598 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1012650
Number of subjects: 189
Study 26323598 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1059778
Number of subjects: 189
Study 24705232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (0.2 mg) administered 2 hours before anesthesia
Number of subjects: 66
Study 24705232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 22760531 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antimicrobial treatment with amoxicillin‐clavulanate for 7 days
Number of subjects: 214
Study 22760531 — intervention group
Group type: COMPARATOR
Intervention: Immediate antimicrobial treatment with amoxicillin‐clavulanate for 7 days
Number of subjects: 214
Study 22760531 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antimicrobial treatment
Number of subjects: 214
Study 20101114 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular matrix
Number of subjects: 0
Study 20101114 — intervention group
Group type: COMPARATOR
Intervention: Moist wound dressing
Number of subjects: 0
Study 18039674 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete abstinence from alcohol
Number of subjects: 120
Study 18039674 — intervention group
Group type: COMPARATOR
Intervention: Any drinking
Number of subjects: 120
Study 18039674 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive %CDT (> or =2.6)
Number of subjects: 120
Study 18039674 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive GGT (> or =50 IU)
Number of subjects: 120
Study 17209507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 15 mg/day
Number of subjects: 5269
Study 17209507 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day
Number of subjects: 5269
Study 17209507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5269
Study 12488380 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. amino acid infusion (4 kJ kg(‐1) h(‐1) starting 2 h before surgery)
Number of subjects: 35
Study 12488380 — intervention group
Group type: COMPARATOR
Intervention: saline infusion
Number of subjects: 35
Study 12488380 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. amino acid infusion
Number of subjects: 35
Study 10625579 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical analgesia cream (EMLA)
Number of subjects: 11
Study 10625579 — intervention group
Group type: COMPARATOR
Intervention: Placebo and untreated areas
Number of subjects: 11
Study 10625579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling (all treatments)
Number of subjects: 11
Study 10625579 — intervention group
Group type: EXPERIMENTAL
Intervention: Pin-pricking (all treatments)
Number of subjects: 11
Study 8858057 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 1100
Study 8858057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study 1536784 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with traditional Chinese medicinal plants for 8 weeks
Number of subjects: 47
Study 1536784 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 47
Study 6492228 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (10 g) with acetaminophen (1 g)
Number of subjects: 8
Study 6492228 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (10 g) with sodium sulfate (18 g) and acetaminophen (1 g)
Number of subjects: 8
Study 6492228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium sulfate (18 g) with acetaminophen (1 g)
Number of subjects: 8
Study 6492228 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1 g) alone
Number of subjects: 8
Study 31827687 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PBMT
Number of subjects: 22
Study 28626088 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved all 5 secondary prevention parameters
Number of subjects: 13616
Study 28626088 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved at least 4 secondary prevention parameters
Number of subjects: 13616
Study 28626088 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 13616
Study 28626088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking status
Number of subjects: 13616
Study 28626088 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline secondary prevention score
Number of subjects: 13616
Study 27020585 — intervention group
Group type: EXPERIMENTAL
Intervention: PHH3 mitotic count
Number of subjects: 100
Study 27020585 — intervention group
Group type: COMPARATOR
Intervention: H&E mitotic count
Number of subjects: 100
Study 27020585 — intervention group
Group type: COMPARATOR
Intervention: Ki67 labeling index (Ki67LI)
Number of subjects: 100
Study 25403147 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms first strategy
Number of subjects: 51
Study 25403147 — intervention group
Group type: COMPARATOR
Intervention: Key first strategy
Number of subjects: 51
Study 25403147 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 51
Study 23422800 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic lobectomy (VATS)
Number of subjects: 65
Study 23422800 — intervention group
Group type: COMPARATOR
Intervention: Conventional lobectomy (thoracotomy)
Number of subjects: 65
Study 23422800 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate analysis
Number of subjects: 65
Study 19262392 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp block with 20 ml 0.5% bupivacaine
Number of subjects: 45
Study 19262392 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration anaesthesia with 0.5% bupivacaine
Number of subjects: 45
Study 19262392 — intervention group
Group type: COMPARATOR
Intervention: Routine anaesthesia (Control group) with opioids
Number of subjects: 45
Study 17161125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (including analgesia suggestions 20 min before and throughout the surgical procedure)
Number of subjects: 30
Study 17161125 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 30
Study 17161125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (hypnosis and control)
Number of subjects: 30
Study 15277915 — intervention group
Group type: COMPARATOR
Intervention: Hemofiltration
Number of subjects: 192
Study 15277915 — intervention group
Group type: COMPARATOR
Intervention: Control (Saline)
Number of subjects: 192
Study 15277915 — intervention group
Group type: COMPARATOR
Intervention: Steroid
Number of subjects: 192
Study 11915634 — intervention group
Group type: EXPERIMENTAL
Intervention: New injection system
Number of subjects: 14
Study 11915634 — intervention group
Group type: COMPARATOR
Intervention: Compression-pack technique
Number of subjects: 14
Study 9765767 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (160 mg 3 times daily for 10 days)
Number of subjects: 84
Study 9765767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 9765767 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 84
Study 7812411 — intervention group
Group type: EXPERIMENTAL
Intervention: High 13C/12C ratio carbohydrates (corn, cane sugar, pineapple, millet)
Number of subjects: 10
Study 7812411 — intervention group
Group type: COMPARATOR
Intervention: Low 13C/12C ratio carbohydrates
Number of subjects: 10
Study 3057329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bay 1099 (25, 50, or 100 mg)
Number of subjects: 6
Study 3057329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bay 1099 (50 mg tid)
Number of subjects: 6
Study 3057329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31166620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.1 mg/kg every 4 weeks
Number of subjects: 138
Study 31166620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.5 mg/kg every 4 weeks
Number of subjects: 138
Study 31166620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 2.0 mg/kg every 4 weeks
Number of subjects: 138
Study 31166620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 28976791 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative epirubicin, cisplatin, and infusional FU (ECF) before and after combined FU and radiotherapy
Number of subjects: 546
Study 28976791 — intervention group
Group type: COMPARATOR
Intervention: Postoperative FU plus LV before and after combined FU and radiotherapy (FU plus LV arm)
Number of subjects: 546
Study 26346429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF diet)
Number of subjects: 897
Study 26346429 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 897
Study 23567902 — intervention group
Group type: EXPERIMENTAL
Intervention: WISE intervention (motivational interviewing and cognitive behavioral therapy)
Number of subjects: 262
Study 23567902 — intervention group
Group type: COMPARATOR
Intervention: Control (education videos)
Number of subjects: 262
Study 23567902 — intervention group
Group type: EXPERIMENTAL
Intervention: WISE intervention
Number of subjects: 262
Study 23567902 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 262
Study 22043668 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep puncture by elongated needle combined with spike-hooked needle and cupping
Number of subjects: 120
Study 22043668 — intervention group
Group type: COMPARATOR
Intervention: Conventional needling and cupping
Number of subjects: 120
Study 22043668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 19922576 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 255
Study 19922576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 255
Study 19922576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 17072268 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA with propofol and remifentanil
Number of subjects: 53
Study 17072268 — intervention group
Group type: COMPARATOR
Intervention: Desflurane-fentanyl anesthesia
Number of subjects: 53
Study 16215865 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention in intervention stores
Number of subjects: 560
Study 16215865 — intervention group
Group type: COMPARATOR
Intervention: Control stores
Number of subjects: 560
Study 12040433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside analogues (NA) including fludarabine (FAMP) and cladribine (2‐CdA)
Number of subjects: 0
Study 12040433 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 0
Study 12040433 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with NA
Number of subjects: 0
Study 9454993 — intervention group
Group type: EXPERIMENTAL
Intervention: PharmaCAL computer-assisted instruction package
Number of subjects: 52
Study 9454993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exposure to PharmaCAL)
Number of subjects: 52
Study 7591550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative meta-analysis of randomized control trials
Number of subjects: 0
Study 7591550 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of meta-analysis on high-quality clinical data
Number of subjects: 0
Study 2568643 — intervention group
Group type: EXPERIMENTAL
Intervention: procyclidine 5 mg t.i.d.
Number of subjects: 33
Study 2568643 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine 25 mg t.i.d.
Number of subjects: 33
Study 2568643 — intervention group
Group type: COMPARATOR
Intervention: haloperidol 4.5 mg t.i.d. (group HPL)
Number of subjects: 33
Study 785432 — intervention group
Group type: EXPERIMENTAL
Intervention: Carticain (Ultracain)
Number of subjects: 60
Study 785432 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracain (Pantocain)
Number of subjects: 60
Study 785432 — intervention group
Group type: COMPARATOR
Intervention: Both Carticain and Tetracain
Number of subjects: 60
Study 31176108 — intervention group
Group type: EXPERIMENTAL
Intervention: Open (high outcome expectancy)
Number of subjects: 23
Study 31176108 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled (low outcome expectancy)
Number of subjects: 23
Study 27899529 — intervention group
Group type: EXPERIMENTAL
Intervention: rTFA (2% of daily energy intake from ruminant TFA)
Number of subjects: 142
Study 27899529 — intervention group
Group type: EXPERIMENTAL
Intervention: iTFA (2% of daily energy intake from industrial TFA)
Number of subjects: 142
Study 27899529 — intervention group
Group type: COMPARATOR
Intervention: wTFA (diet without TFA)
Number of subjects: 142
Study 26283145 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation + linear ablation + complex fractionated atrial electrogram (CFAE) ablation
Number of subjects: 130
Study 26283145 — intervention group
Group type: COMPARATOR
Intervention: Circumferential pulmonary vein ablation + linear ablation
Number of subjects: 130
Study 23773796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab every 4 weeks
Number of subjects: 191
Study 23773796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab every 6 weeks
Number of subjects: 191
Study 23773796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab every 8 weeks
Number of subjects: 191
Study 22214714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg, thrice a day) for 4 weeks
Number of subjects: 83
Study 22214714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (10 μM) in vitro
Number of subjects: 83
Study 22214714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine (10 μM) in vitro
Number of subjects: 83
Study 22214714 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolipram (10 μM) in vitro
Number of subjects: 83
Study 22214714 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobutyl‐methylxanthine (IBMX, 100 μM) in vitro
Number of subjects: 83
Study 19368965 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 200/6 microg twice daily plus as-needed
Number of subjects: 127
Study 19368965 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol 800/12 microg twice daily
Number of subjects: 127
Study 16716321 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of prednisone (20 mg/d), aspirin (100 mg/d), folate (5 mg every second day), and progesterone (20 mg/d) for the first 12 weeks of gestation.
Number of subjects: 80
Study 16716321 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 80
Study 16716321 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of prednisone, aspirin, folate, and progesterone.
Number of subjects: 80
Study 14760337 — intervention group
Group type: EXPERIMENTAL
Intervention: Das AngelWings device for closure of ASD or PFO
Number of subjects: 30
Study 11325461 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood state
Number of subjects: 60
Study 11325461 — intervention group
Group type: COMPARATOR
Intervention: Positive mood state
Number of subjects: 60
Study 9134638 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-factor VIII inhibitors (a-fVIII)
Number of subjects: 170
Study 9134638 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus anticoagulants (LAs)
Number of subjects: 170
Study 9134638 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from a-fVIII to LA pattern
Number of subjects: 170
Study 7934158 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF with standard induction chemotherapy (TAD)
Number of subjects: 14
Study 2849968 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium 0.07 mg kg‐1
Number of subjects: 39
Study 2849968 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 39
Study 2849968 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium
Number of subjects: 39
Study 2849968 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 39
Study 29194612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocurcumin therapy for 6 months
Number of subjects: 50
Study 29194612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocurcumin therapy
Number of subjects: 50
Study 28753849 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-201 (200-1800mg, oral, twice daily)
Number of subjects: 134
Study 25887096 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release mixed amphetamine salts (60 mg)
Number of subjects: 126
Study 25887096 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release mixed amphetamine salts (80 mg)
Number of subjects: 126
Study 25887096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 23694983 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk of cervical cancer
Number of subjects: 388
Study 23694983 — intervention group
Group type: EXPERIMENTAL
Intervention: History of marriage
Number of subjects: 388
Study 23694983 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling adequately informed about cervical cancer by health care providers
Number of subjects: 388
Study 23694983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to have cervical cancer screening in the future
Number of subjects: 388
Study 23694983 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to undergo screening regardless of cost
Number of subjects: 388
Study 21951433 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized mindfulness training for eight weeks, followed by eight sessions of e-coaching and supporting elements (fruit and snack vegetables at the workplace, lunch walking routes, buddy system)
Number of subjects: 0
Study 21951433 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 0
Study 18485309 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 4% with adrenalin 1:200,000
Number of subjects: 50
Study 18485309 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% with adrenalin 1:100,000
Number of subjects: 50
Study 17175661 — intervention group
Group type: EXPERIMENTAL
Intervention: Zemaira (study drug)
Number of subjects: 44
Study 17175661 — intervention group
Group type: COMPARATOR
Intervention: Prolastin (control drug)
Number of subjects: 44
Study 12547873 — intervention group
Group type: EXPERIMENTAL
Intervention: HIM2 (0.5 mg/kg)
Number of subjects: 18
Study 12547873 — intervention group
Group type: EXPERIMENTAL
Intervention: HIM2 (1.0 mg/kg)
Number of subjects: 18